LONP1 and plasma cell myeloma: However, these results can be differently interpreted: patients with multiple myeloma cells expressing high levels of LonP1 are more resistant to bortezomib (causality), or higher expression of LonP1 is an epiphenomenon in cancers that show more aggressive growth under therapy (correlation).